We have investigated seroreactivity against Plasmodium falciparum crude parasite antigens, the P. falciparum ring-infected erythrocyte surface antigen (Pf155/RESA), as well as against two synthetic peptides (EENV)6 and (EENVEHDA)3 that represent important epitopes of Pf155/RESA. The study population consisted of 421 children and adult Thais living in an area with moderate malaria transmission. We related these serologic findings to some important epidemiologic baseline data collected in the study area. The parasite rate in study subjects was 18.76%. Sixty-two percent were seropositive to crude P. falciparum antigens, 30.3% to the Pf155/RESA antigen, 23.05% to (EENV)6, and 20.17% to (EENVEHDA)3. Antibody responses to crude P. falciparum antigens and to Pf155/RESA were age dependent and increased with exposure. There was evidence that Pf155/RESA antibodies might play a role in protective immunity in this population. Since Pf155/RESA is a potential vaccine candidate antigen, the information obtained from these field studies will provide some seroepidemiologic baseline data for subsequent vaccine trials.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4269/ajtmh.1992.47.554 | DOI Listing |
ACS Infect Dis
March 2025
Department of Biotechnology, All India Institute of Medical Sciences, New Delhi 110029, India.
Malaria, caused by a protozoan parasite of the genus is a severe infectious disease with life-threatening consequences that has burdened mankind for centuries. Although () malaria is more prevalent globally than () malaria, India bears the largest burden of malaria, with over 3.6 million cases accounting for ∼48% of global malaria cases.
View Article and Find Full Text PDFmBio
March 2025
Department of Microbiology and Molecular Genetics, The Kuvin Center for the Study of Infectious and Tropical Diseases, IMRIC, The Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Unlabelled: The protozoan parasite , which is responsible for the deadliest form of human malaria, accounts for over half a million deaths a year. These parasites proliferate in human red blood cells by consecutive rounds of closed mitoses called schizogony. Their virulence is attributed to their ability to modify the infected red cells to adhere to the vascular endothelium and to evade immunity through antigenic switches.
View Article and Find Full Text PDFVaccine
March 2025
Indian Institute of Science Education and Research, Pashan, Pune, Maharashtra 411008, India. Electronic address:
Plasmodium falciparum-induced malaria remains a fatal disease affecting millions of people worldwide. Mainly, the blood stage of malaria is highly pathogenic and symptomatic, rapidly damaging the host organs and occasionally leading to death. Currently, no vaccines are approved for use against the blood stage of malaria.
View Article and Find Full Text PDFBioinform Biol Insights
March 2025
Discipline of Genetics, School of Life Sciences, College of Agriculture, Engineering and Sciences, University of KwaZulu-Natal, Durban, South Africa.
is the most fatal species of malaria parasites in humans. Attempts at developing vaccines against the malaria parasites have not been very successful even after the approval of the RTS, S/AS01 vaccine. There is a continuous need for more effective vaccines including sexual-stage antigens that could block the transmission of malaria parasites between mosquitoes and humans.
View Article and Find Full Text PDFFront Cell Infect Microbiol
March 2025
Department of Parasitology and Medical Entomology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Introduction: The incidence of malaria in Indonesia has declined significantly over the last few decades. Thus, a demand for more sensitive techniques to describe low levels of transmission in the country is important. This study was conducted to evaluate antibody response to and in an area nearing elimination in North Sumatera Province, Indonesia.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!